Skip to main content
. 2019 Jun 17;9:8671. doi: 10.1038/s41598-019-45191-2

Figure 4.

Figure 4

Acquisition of a senescent phenotype by CAP He treated ASC and dermal fibroblatsts. (A) ASC and dermal fibroblasts were treated (CAP or NT) and nuclear p16 was imaged by immunofluorescence. Images were acquired using the high content imaging system Operetta (Perkin Elmer, lens x20) to quantify p16 nuclear spots number per cell and fluorescence intensity per cell (means of 5 fields). (B) Senescence associated-morphological change was observed 7 and 14 days after treatment. Cells morphology was evaluated by DAPI (nuclear) and β-tubulin (cytoskeleton) labeling using the high content imaging system Operetta (Perkin Elmer, lens x20). Pictures were taken with a Nikon, Eclipse, TE2000-S microscope (x200 magnification) (n = 4). (C) Nuclear size was additionally quantified (n = 4). (D) Senescence associated-β-galactosidase (SA-β-gal) was quantified 5 and 7 days after treatment by flow cytometry with a substrate (C12-FDG). Quantification is represented by the Mean of Fluorescence Intensity (MFI) normalized to the same condition without labelling. SA-β-gal was also evaluated by biochemical detection (blue staining) and pictures were taken at day 7 with a Nikon, Eclipse, TE2000-S microscope (ASC, n = 3 to 4; fibroblast, n = 3 to 5). (E) Senescence associated cytokine secretion was evaluated in treated cells supernatant for IL-6 and IL-8 by ELISA (n = 3 to 6). Data represent mean ± SEM of independent experiments as indicated (n).